

Management Presentation Financial Results for 9M2014 01 December, 2014



Disclaimer

You must read the following before continuing.

The following applies to the company presentation (the "company presentation") following this important notice, and you are therefore advised to read this important notice carefully before reading, accessing or making any other use of the company presentation. In accessing the company presentation, you agree to be bound by the following terms and conditions, including any modifications to them any time that you receive any information from us as a result of such access. The information contained in this company presentation has been prepared by Avangardco investments public limited ("Avangard" or the "company").

This document does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in Australia. Canada, Japan, Ukraine or the United States or in any jurisdiction to whom or in which such offer or solicitation is unlawful. This presentation is not an offer for sale of securities in the United States or any other jurisdiction. Any securities which are the subject of such offer have not been, and will not be, registered under the U.S. Securities act of 1933, as amended (the "securities act"), or the securities laws of any state of the United States or other jurisdiction and may not be offered or sold within the united states or to, or for the account or benefit of, U.S. Persons (as defined in regulation s under the securities act), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the securities act and any applicable state or local securities laws. Any offer of such securities will be made by means of an offering document that will contain detailed information about the company and its management, including financial statements. Any investment decision should be made on the basis of the final terms and conditions of the securities and the information contained in such offering document and not on the basis of this presentation which does not constitute or form part of an offer or solicitation of an offer to purchase or subscribe for any securities. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia. Canada, Japan, or Ukraine or to, or for the account or benefit of, any national, resident or citizen of Australia. Canada, Japan, or Ukraine. The offer and sale of the securities referred to herein has not been and will not be registered under the securities act or under the applicable securities laws of Australia, Canada, Japan, or Ukraine. There will be no public offer of the securities in the United States.

This company presentation is only addressed to and directed at persons in member states of the European economic area who are "qualified investors" within the meaning of article 2(1)(e) of the prospectus directive (directive 2003/71/ec) ("qualified investors"). In addition, in the United Kingdom, this company presentation is being distributed only to, and is directed only at (i) investment professionals within the meaning set out in article 19(5) of the financial services and markets act 2000 (financial promotion) order 2005, as amended (the "order") and qualified investors falling within article 49(2)(a) to (d) of the order, and (ii) persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons"). This company presentation must not be acted on or relied on (i) in the United Kingdom, by persons who are not relevant persons, and (ii) in any member state of the European economic area other than the United Kingdom, relevant persons, and (ii) in the United Kingdom, relevant persons, and (ii) in any member state of the European economic area other than the United Kingdom, relevant persons, and will be engaged in only with such persons.

This company presentation may not be used in any jurisdiction where such use is not authorised or is unlawful. The distribution of this company presentation in certain jurisdictions may be restricted by law. Persons in whose possession this company presentation may come are required to inform themselves about and to observe such restrictions.

Each recipient hereof, by virtue of receiving this company presentation, will be deemed to have acknowledged, represented and agreed that it is not a U.S. Person and is acting for its own account or for the account of a non U.S. Person in an offshore transaction (as defined in regulation s under the securities act) and (a) if it is in the United Kingdom, it is a relevant person, and/or a relevant person who is acting on behalf of, relevant persons in the United Kingdom and/or qualified investors to the extent it is acting on behalf of persons or entities in the United Kingdom or the European economic area; or (b) if it is in any member state of the European economic area other than the United Kingdom, it is a qualified investor and/or a qualified investor acting on behalf of, qualified investors or relevant persons, to the extent it is acting on behalf of persons or entities in the European economic area or the United Kingdom.

This company presentation is confidential and is being provided to you solely for your information and may not be reproduced in any form or forwarded or further distributed to any other person or published, in whole or in part, for any purpose whatsoever. Any forwarding, distribution or reproduction of this company presentation in whole or part is unauthorised. Failure to comply with this directive may result in a violation of the securities act or the applicable laws of other jurisdictions. the provision of this company presentation doesn't constitute or shall not be relied upon as constituting, the giving of investment (or other) advice by the company or any other shareholders, employees representatives or affiliates thereof. Neither Avangard nor its respective subsidiaries, associates, directors, employees, agents or advisors (such directors, employees, agents or advisors being hereafter referred to as "representatives"), makes any representation or warranty (express or implied) as to the adequacy, accuracy, reasonableness or completeness of the information contained in this company presentation or of any additional information, and such parties or entities expressly disclaim any and all responsibility or liability (other than in respect of fraudulent misrepresentation) based on or relating to the accuracy or sufficiency thereof, or for any errors or omissions from, this company presentation or any additional information or based on or relating to the recipient's reliance or use or the reliance or use by any of its associates or representatives on or of this company presentation or any additional information, or any other written or oral communications transmitted to the recipient or any of its associates or representatives or any other person in the course of its or their evaluation of an investment in the company.

Forward looking statements this company presentation includes statements that are, or may be deemed to be, "forward looking statements". These forward looking statements can be identified by the use of forward looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "may", "will" or "should" or, in each case their negative or other variations or comparable terminology. These forward looking statements include all matters that are not historical facts. They appear in a number of places throughout this company presentation and include statements regarding the intentions, beliefs or current expectations of the company. By their nature, forward looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward looking statements are not guarantees of future performance. The company's actual performance, results of operations and financial condition may differ materially from the impression created by the forward looking statements contained in this company presentation.

Subject to its legal and regulatory obligations, Avangard expressly disclaims any obligation to update or revise any forward looking statement contained herein to reflect any change in expectations with regard thereto or any change in events, conditions or circumstances on which any statement is based. Neither troika nor any of its respective affiliates undertake to provide the recipient hereof with access to any additional information or to update this company presentation or to correct any inaccuracies herein which may become apparent.

Any recipient of this company presentation is solely responsible for assessing and keeping under review the business, operations, financial condition, prospects, creditworthiness, status and affairs of the company.

In no circumstances shall the delivery of this company presentation imply that no negative change may occur in the business of the company after the date of issuance of this company presentation, or any date of amendment and/or addition thereto. Financial information and rounding

Certain financial information contained in this company presentation has been extracted from the company's unaudited management accounts and financial statements prepared in accordance with Ukrainian Accounting Standards ("UAS"). The areas in which management accounts or UAS financial statements differ from International Financial Reporting Standards ("IFRS") and/or U.S. Generally accepted accounting principles could be significant and you should consult your own professional advisors and/or conduct your own due diligence for a fuller understanding of the significance of such differences and any impact such differences may have on the relevant financial information contained in this company presentation. Some numerical figures included in this company presentation have been subject to rounding adjustments. Accordingly, numerical figures shown as totals in certain tables may not be an arithmetic aggregation of the figures that preceded them. Certain information presented herein (including market data and statistical information) has been obtained from various sources which the company considers to be reliable. However, the company makes no representation as to, and accepts no responsibility or liability whatsoever for, the accuracy or completeness of such information.

Business and Operations Update
Financial Results

Appendix: Financial Snapshot

1. Business and Operations Update

Operational performance in 9M2014 vs. 9M2013

th tonnes

15.5

9M2013

17.7

9M2014

+15%

Shell eggs

- Production remains flat at 5.114 bn pcs
- Sales to third parties down by 6% to 3.499 bn pcs
- Export up by 32% to 462 mn pcs
- Average sales price up by 9% to 0.71 UAH (excl. VAT)

Egg products

bn pcs

5.1

- Eggs processed into dry egg products up by 20% to 1.518 bn pcs
- Dry egg products produced up by 15% to 17.7 th tonnes
- Sales up by 17% to 15.9 th tonnes

Production of shell eggs,

5.1

9M2014

- Export up by 13% to 13.0 th tonnes
- Average sales price down by 14% to 6.51 USD

Poultry flock

- Total flock down by 18% to 25.9 mn heads as at 30 September 2014
- The actual number of laying hens down by 25% YoY and by 31% from the YE2013 to 18.5 mn heads as at 30 September 2014 due to conflict in East Ukraine and the annexation of Crimea
- New poultry complexes Avis and Chornobaivske worked at 92% capacity or 10.3 mn laying hens as at 30 September 2014



Total number of laying hens,

Source: Company data

9M2013

Diversified sales structure: growing focus on export and retail sales

Production of shell eggs by volume, %



Eggs sales to third parties by volume, %



•Production of shell eggs remained flat

• 6% decrease in sales of shell eggs to third parties due to the 20% increase in further processing of shell eggs into dry egg products to meet demand in export markets

• redistribution of shell eggs sales channels:

- 32% increase in export sales (13% share in total sales)
- 37% share of retail sales with the five(fold increase in the sales of packaged eggs "Kvochka" to 160 mn pieces

• 13% increase in export of dry egg products (82% share in total sales)

On September 30, 2014, the "Imperovo Foods" egg processing plant received EU approval to export egg products

On August 18, 2014, the Company received a certificate of Kosher status of its shell eggs and egg products, and is currently getting ready to make the first shipment to Israel.

Egg products sales by volume, %



6

2. Financial Results

Key financial highlights

\$'000	3Q2013	3Q2014	%	9M2013	9M2014	%
Revenue	162,254	92,013	(43%)	466,542	354,693	(24%)
Average shell egg price, UAH/egg	0.69	0.80	15%	0.65	0.71	9%
Average shell egg price, USD/egg	0.086	0.063	(27%)	0.081	0.064	(21%)
Average egg products price USD/k	g 7.57	6.61	(13%)	7.61	6.51	(14%)
Cost of sales	(102,967)	(70,210)	(32%)	(309,368)	(<mark>261,142)</mark>	(16%)
Cost per egg, UAH/egg	0.41	0.60	44%	0.42	0.51	21%
Cost per egg, USD/egg	0.052	0.047	(9%)	0.052	0.046	(12%)
Cost per egg products, USD/kg	4.55	3.51	(23%)	4.52	3.92	(13%)
Gross profit	67,993	21,288	(69%)	186,597	102,085	(45%)
Net Profit/Loss	56,411	(57,735)	(202%)	161,968	(5,747)	(104%)
EBITDA	70,372	29,678	(58%)	205,738	108,628	(47%)
EBITDA margin	43%	32%	(11%)	44%	31%	(13%)

• the decrease in the <u>consolidated revenue</u> was primarily due to the Ukrainian hryvnia devaluation against the US dollar by approximately 38% as well as the decline in the sales price of dry egg products by 14% YoY and in the sales of shell eggs to third parties by 6% YoY. However, the increase in export sales coupled with growth of sales to retail chains has partially offset the decline in the Company's consolidated revenue;

• the <u>average sales price of shell eggs in the Ukrainian</u> <u>hryvnia</u> increased by 9% YoY to 0.71 UAH per unit (excl. VAT) as a result of the seasonal growth, however the Ukrainian hryvnia devaluation reduced the positive effect of the price growth;

• the increase in <u>cost per egg in the Ukrainian hryvnia</u> was due to higher fodder prices and other components;

• the decrease in <u>cost per unit for eggs and egg products</u> in the US Dollars was due to the Ukrainian hryvnia devaluation;

• <u>net loss</u> was due to a one-off impairment charge on assets in Crimea and Eastern Ukraine and losses on foreign exchange of US\$49.5 mln.

Average FX UAH/USD	1Q13	1Q14	Δ	2Q13	2Q14	Δ	3Q13	3Q14	Δ	9m13	9m14	Δ
Average FX OAH/ 05D	7.993	8.863	+11%	7.993	11.696	+46%	7.993	12.577	+57%	7.993	11.059	+38%

Revenue and EBITDA margin bridges 9M2013 vs 9M2014



* Depreciation is not included

Source: Company data

Key financial indicators

-			shell e	ggs					egg p	products		
<u>USD '000</u>	3Q2013	3Q2014	%	9M2013	9M2014	%	3Q2013	3Q2014	%	9M2013	9M2014	%
Revenue	107,366	67,951	(37%)	306,123	226,009	(26%)	46,374	20,515	(56%)	103,942	103,312	(1%)
Export sales, %	12%	23%	11%	14%	22%	8%	85%	96%	11%	85%	82%	(3%)
Revenue contribution, %	66%	74%	8%	66%	64%	(2%)	29%	22%	(7%)	22%	29%	7%
Gross profit	53,052	14,711	(72%)	131,425	60,794	(54%)	15,453	7,650	(50%)	42,289	41,064	(3%)
Gross profit contribution, %	78%	69%	(9%)	70%	60%	(10%)	23%	36%	13%	23%	40%	17%
Gross profit margin, %	49%	22%	(27%)	43%	27%	(16%)	33%	37%	4%	41%	40%	(1%)

Sales revenue structure by segment



- A revenue share of two main segments (shell eggs and egg products) increased by 5% in total sales structure compared to 9M2013 and reached 93% of consolidated revenue in 9M2014;
- An export revenue share of two main segments (shell eggs and egg products) increased by 9% in those segments sales structure and reached 41% consolidated revenue in those segments in 9M2014 vs 9M2013 due to increase in export volumes;
- 9M2014 revenue in shell eggs segment decreased by 26% vs. 9M2013 due to the Ukrainian hryvnia devaluation and the decline in the sales of shell eggs to third parties, that was partially offset by the increase in export sales and sales to retail chains;
- A slight decline in dry egg products export revenue resulted from a decrease in sales to Jordan during the third quarter of 2014 in connection with the military conflict in Iraq as Jordan has reduced the volume of purchases of dry egg products.

Key segment quarter results

Key financial indicators

	Sł	nell eggs		Egg products			Consolidated		
USD '000	2Q2014	3Q2014	%	2Q2014	<mark>3Q2014</mark>	%	2Q2014	3Q2014	%
Revenue	62,457	67,951	9%	31,471	20,515	(35%)	110,481	92,013	(17%)
Export sales, %	25%	23%	(2%)	87%	96%	9%	39%	38%	(1%)
Revenue contribution, %	57%	74%	17%	28%	22%	(6%)			
Gross profit	10,603	14,711	39%	15,279	7,650	(50%)	21,051	21,289	1%
Gross profit contribution, %	50%	69%	38%	73%	36%	(51%)			
Gross profit margin, %	17%	22%	5%	49%	37%	(12%)	19%	23%	4%

Shell eggs sales, bn pcs







Cost of finished goods breakdown

USD '000	9M2013	9M2014	change
Raw materials	250,299	210,658	(16%)
Payroll of production personnel and related charges	15,790	12,258	(22%)
Depreciation	18,039	14,765	(18%)
Services provided by third parties	23,687	21,789	(8%)
Other	130	115	(12%)
Total COGS	307,945	259,585	(16%)

Change in cost of shell egg, UAH/egg



Cost of finished goods structure,



20% 5% 3% UAH 0.51 4% 68% 68% abor char backing vitamin/vaccine other

Cost of sales of shell egg structure in 3Q2014 vs. 2Q2014



Cost of sales of components for shell egg production, UAH/pcs

	2Q2014	3Q2014	change
fodder*	0.35	0.38	0.03
Grains	0.10	0.09	0.00
Oils	0.19	0.21	0.02
Other	0.06	0.07	0.01
labor	0.02	0.03	0.01
depreciation	0.01	0.02	0.00
packing, vitamin	0.02	0.03	0.01
others	0.10	0.14	0.05
total	0.50	0.60	0.10

*in volume terms fodder in average receipt consists of grains (50%), oils (41%) and other (9%)

In 3Q2014, cost of sales of shell eggs increased as a results of increased production costs

Price of fodder components , UAH/ton

	2	2Q2014		3Q2014		
_	Avangard	Market	diff	Avangard	Market	diff
fodder	2,793	3,172**	14%	2,999	3,040**	1%
Grains	1,538	1,876	22%	1,560	1,659	6%
Oils	3,668	4,176	14%	4,030	4,010	0%
Other	5,706	-	-	6,187	-	-

** in Avangard's average receipt volume terms Source: Company data, APK inform

٠

Debt and cash&cash equivalents

Debt structure

USD '000	31.12.2013	30.06.2014	<mark>30.09.2014</mark>	
Total debt	322,828	342,177	344,936	
Long(term	258,626	280,259	281,021	
Short(term	50,000	50,000	50,000	
Current portion				
of long(term debt	14,202	11,918	13,915	
Cash&cash equivalents	156,804	236,080	157,605	
Net Debt	166,024	106,097	187,331	
				covenant
Net debt/LTM EBITDA	0.6	0.4	0.9	
Total debt/LTM EBITDA	1.1	1.4	1.7	<=3.0

Loan portfolio servicing schedule as at 30.09.2014, USD mn **

- 99% of total debt is held in USD and EUR;
- Major debt* amounts are held in the European banks, such as Landesbank Berlin AG, Deutsche bank AG (London branch), Credit Suisse, Intesa Sanpaolo S.p.A (London branch), Rabobank;
- Loans portfolio structure by currency:
 - USD 72%
 - EUR 27%
 - UAH 1%
- As at 30 September 2014, cash&cash equivalents decreased due to the increase in 3Q2014 trade receivables, which resulted from the extension of payment periods upon the lower demand for products following an unstable situation in Eastern Ukraine. There was a further increase in inventories and a decrease in prepayments from customers and exchange losses on translation into the presentation currency;
- Cash&cash equivalents are held on the accounts in the European banks;
- Low financial leverage, which complies with the covenants;
- Avangard completed its investment programme and expects cash flow to increase in the future.



Source: Company data

Appendix: Financial Snapshot

Balance Sheet

\$'000	2013	9M2014	change, %
NON-CURRENT ASSETS	1,183,740	759,163	(36%)
Property, plant and equipment	1,103,630	688,590	
Non-current biological assets	76,678	31,892	
Deferred tax assets	3,059	1,690	
VAT government bonds	-	36,961	
Other non-current assets	373	30	
CURRENT ASSETS	635,175	480,856	(24%)
Inventories	193,382	122,165	
Current biological assets	60,648	33,255	
Trade accounts receivable, net	88,972	97,263	
Prepaid income tax	85	45	
Prepayments and other current assets, net	30,845	17,237	
Taxes recoverable and prepaid	104,439	53,286	
Cash and cash equivalents	156,804	157,605	
TOTAL ASSETS	1,818,915	1,240,019	(32%)
TOTAL EQUITY	1,447,098	865,736	(40%)
NON(CURRENT LIABILITIES	263,414	283,951	8%
CURRENT LIABILITIES	108,403	90,332	(17%)
Loans and bonds	64,504	63,992	
Trade Accounts Payable	15,084	8,496	
Other Payables	28,815	17,844	
TOTAL LIABILITIES	371,817	374,283	1%
TOTAL EQUITY AND LIABILITIES	1,818,915	1,240,019	(32%)
NET DEBT at the date	166,024	187,331	13%

Source: Company data

\$'000	9M2013	9M2014	change, %
REVENUE	466,542	354,693	(24%)
Income from revaluation of biological assets at fair value	29,423	8,534	
Cost of sales	(309,368)	(261,142)	
			(
GROSS PROFIT	186,597	102,085	(45%)
General administrative expenses	(12,417)	(9,160)	
Distribution expenses	(18,525)	(15,018)	
Income from government grants and incentives	214	110	
Impairment of non current assets	(15)	(25,751)	
Income from special VAT treatment	32,632	33,153	
Other operating income/expenses, net	(1,513)	(17,781)	
OPERATING PROFIT/(LOSS)	186,973	67,638	(64%)
Financial income	90	143	
Financial expenses	(24,896)	(23,778)	
Gains/(losses) on exchange	(698)	(49,461)	
PROFIT BEFORE TAX	161,469	(5,458)	(103%)
Income tax expenses	499	(289)	
PROFIT/(LOSS) FOR THE PERIOD	161,968	(5,747)	(104%)
EBITDA	205,738	108,628	(47%)
EBITDA margin	44.1%	30.6%	(13%)

Cash Flow Statement

\$'000	9M2013	1H2014	9M2014
PROFIT BEFORE INCOME TAX	161,470	51,381	(5,458)
OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	175,127	91,574	108,831
(Increase)/decrease in net working capital	(25,899)	8,761	(60,680)
Interest paid	(6,407)	(5,005)	(6,941)
Income tax paid	(65)	(41)	(41)
NET CASH GENERATED FROM/(USED IN) OPERATING ACTIVITIES	142,756	95,289	41,169
Purchases of PP&E	(181,279)	(33,686)	(55,011)
Interest received	90	83	143
NET CASH GENERATED FROM/(USED IN) INVESTING ACTIVITIES NET CASH GENERATED FROM/(USED IN)	(181,189)	(33,603)	(54,868)
FINANCING ACTIVITIES	(44,078)	12,131	21,269
NET INCREASE/(DECREASE) IN CASH	(82,511)	73,817	7,571
Cash at the beginning of the year	203,504	156,804	156,804
Effects of translation into presentation currency	(12)	5,459	(6,770)
Cash at the end of the period	120,981	236,080	157,605